映恩生物-B（09606）今日盘中大涨5.01%，引发市场关注。截至发稿时，该股报216.6港元，成交额达1.49亿港元。
消息面上，公司将在即将举行的2025年美国临床肿瘤学会（ASCO）年会上公布两项重要研究结果。这两项研究分别涉及HER3 ADC DB-1310和B7H3 ADC DB-1311/BNT324，将以口头报告形式进行展示。ASCO年会将于5月30日至6月3日在美国芝加哥举行，相关研究摘要全文将于5月23日在ASCO官方网站发布。
此外，国泰海通发布的最新研报也为映恩生物-B带来利好。研报指出，公司专注于ADC新药研发，并已达成多项对外授权。其中，DB-1303被认为优于对标产品Enhertu，处于全球领先地位；DB-1311在小细胞肺癌（SCLC）和去势抵抗性前列腺癌（CRPC）治疗方面显示出潜力。研报还强调了公司丰富的产品管线和不断扩大的ADC布局。这些积极因素共同推动了映恩生物-B股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.